OncoMatch/Clinical Trials/NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Is NCT05552222 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for multiple myeloma.
Treatment: Teclistamab · Daratumumab · Lenalidomide · Dexamethasone · Talquetamab — The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any therapy for multiple myeloma or smoldering myeloma
Exception: short course of corticosteroids (not to exceed total of 160 mg dexamethasone or equivalent)
Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams [mg] dexamethasone or equivalent)
Cannot have received: systemic corticosteroids
received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (>=) 20 mg of dexamethasone within 14 days before randomization
Cannot have received: plasmapheresis
Had plasmapheresis within 28 days of randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- University of Arizona Cancer Center · Tucson, Arizona
- UCSF Fresno · Clovis, California
- City of Hope Duarte · Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center · Irvine, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify